The INTERPRET project was a multicentre European collaboration, carried out from 2000 to
2002, which developed a decision‐support system (DSS) for helping neuroradiologists with …

Glioblastomas (GB) are brain tumours with poor prognosis even after aggressive therapy.
Improvements in both therapeutic and follow‐up strategies are urgently needed. In previous …

Glioblastoma (GBM) causes poor survival in patients even when applying aggressive
treatment. Temozolomide (TMZ) is the standard chemotherapeutic choice for GBM treatment …

Background Pattern Recognition techniques can provide invaluable insights in the field of
neuro-oncology. This is because the clinical analysis of brain tumors requires the use of non …

Characterization of glioblastoma (GB) response to treatment is a key factor for improving
patients' survival and prognosis. MRI and magnetic resonance spectroscopic imaging …

Non‐invasive monitoring of response to treatment of glioblastoma (GB) is nowadays carried
out using MRI. MRS and MR spectroscopic imaging (MRSI) constitute promising tools for this …

Glioblastoma (GBM) is the most common aggressive primary brain tumor in adults, with a
short survival time even after aggressive therapy. Non-invasive surrogate biomarkers of …

Background Intrauterine growth restriction (IUGR) is a risk factor for abnormal
neurodevelopment. We studied a rabbit model of IUGR by magnetic resonance imaging …

Purpose Enhanced cell proliferation in tumors can be associated with altered metabolic
profiles and dramatic microenvironmental changes. Downfield magnetic resonance …

Dimethyl sulfoxide (DMSO) is commonly used in preclinical studies of animal models of high‐
grade glioma as a solvent for chemotherapeutic agents. A strong DMSO signal was detected …